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Endothelin, the Bad Actor in the
Play: A Marker or Mediator of
Cardiovascular Disease*
Prakash C. Deedwania, MD, FACC
San Francisco, California
Endothelins (ETs) are a family of three endothelium-
derived 21 amino acid vasoactive peptides (1–3). Of these,
ET-1 possesses the most potent vasoconstrictive properties
described to date (1,2). Although identified just over 10
years ago, there has already been a phenomenal amount of
research conducted regarding the role of ET-1 in cardio-
vascular disorders (3–19). Endothelin-1 has been incrimi-
nated as playing an important role in the whole spectrum of
cardiovascular diseases, including systemic hypertension,
atherosclerosis, acute ischemic syndromes, heart failure,
stroke and pulmonary hypertension (5–19).
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Although it is well-known that ET-1 causes dose-
dependent vasoconstriction by increasing intracellular
Ca11, it has several other important biological actions,
including mitogenic properties, stimulation, secretion and
increased activity of several key hormones and autacoids
such as angiotensin II, aldosterone, nitric oxide, arginine-
vasopressin, and prostacyclin (2,3). The production and
release of ET-1 is also regulated by other vasoactive sub-
stances like angiotensin II, catecholamines, arginine vaso-
pressin, thrombin and insulin (2–5). Because of these
intricate relationships between ET-1 and other vasoactive
substances, it is often difficult to distinguish whether ET is
a mediator or a marker.
The biological effects of ET are mediated by two different
receptors, ETA and ETB, which have different pharmaco-
logical properties and distribution in various tissues (2–4).
The ETA receptors, which are found predominantly on
vascular smooth cells, are involved in mediating vasocon-
striction and mitogenic effects of ET-1, whereas ETB
receptors, which exist in endothelial cells, predominantly
mediate vasodilation by release of EDRFs (nitric oxide and
prostacyclin) (2,3). In addition, ETB receptors may be
involved in the release of aldosterone from zona glomerulosa
and to a lesser extent may also mediate vasoconstriction and
mitogenic effects of ET, especially in disease states. Al-
though ET-1 and ET-3 have equal affinity for ETB recep-
tors, ET-1 has significantly greater affinity for ETA recep-
tors. The ETs bind tightly to their receptors in a “pseudo-
reversible” manner, and their slow dissociation from
receptor sites probably accounts for the prolonged action of
ETs (2). A clear understanding of receptor pharmacology is
crucial because, in patients with cardiovascular disorders
where ET-1 levels are chronically increased, there could be
perturbation in the function of ET receptors.
The significance of alterations in ET receptor function is
illustrated in the article by Cowburn et al. in this issue of the
Journal of the American College of Cardiology (20). This study of
patients with left ventricular systolic dysfunction (LSVD)
demonstrated that the infusion of equimolar concentration of
ET-3, which is a relatively selective ETB receptor agonist,
resulted in a similar degree of vasoconstriction as that produced
by ET-1 (20). These findings suggest that, in contrast to their
predominantly vasodilatory effects observed in normal subjects,
the stimulation of ETB receptors in patients with LVSD
mediates systemic vasoconstriction (20). Although the precise
reason for this altered response cannot be ascertained from the
findings reported in the paper by Cowburn et al., it is
reasonable to assume that endothelin receptor functions are
perturbed in patients with LVSD and CHF. It is conceivable
that, in patients with CHF, ET receptors are downregulated,
resulting in attenuated response to ET-1 infusion. Conversely,
it is also possible that ETB receptor stimulation cannot produce
vasodilation in patients with CHF because of the associated
endothelial dysfunction, which prevents the increase in nitric
oxide production usually observed secondary to ETB receptor
stimulation. The authors suggested that it is possible that
ET-3 could mediate vasoconstriction by ETC receptors, al-
though such receptors have not yet been isolated in humans
(20). A clear understanding of the altered receptor physiology
and responsiveness of ET receptors is essential before any
significant investment is made regarding the evaluation of ET
receptor blockers in chronic heart failure (CHF). This is
particularly relevant because there are a number of compounds
that are now available in this class and some of them are
nonselective (ETA/ETB) whereas others are ETA selective
blocking agents. If the results of the study reported by
Cowburn et al. are reinforced by other studies, it would seem
that nonselective ETA/ETB receptor blockers would be pref-
erable to achieve maximum vasodilation and hemodynamic
benefits in patients with CHF (20).
However, the issue is much more complex, because
findings of an earlier article published in the Journal of the
American College of Cardiology by Wada et al. (18) showed
that, in dogs with CHF induced by rapid ventricular pacing,
only selective ETA receptor blockade was associated with
favorable effects on hemodynamic parameters and diuresis,
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whereas ETB receptor blockade had reverse hemodynamic
effects. Also, results of the REACH-1 study reported at the
71st Scientific Session of the American Heart Association
indicated that bosentan, a nonselective ETA/ETB receptor
blocker, resulted in favorable hemodynamic effects in pa-
tients with CHF. However, in the REACH-1 study there
was no significant improvement in the exercise capacity of
patients treated with bosentan. These findings showing
dissociation between hemodynamic improvement and func-
tional capacity suggest that blockade of ETB receptors
might have prevented the vasodilatory response necessary
for increased blood flow to the skeletal muscles during
exercise (19). Furthermore, treatment with bosentan was
also associated with abnormalities in liver function tests,
which might prevent its clinical development. Although
there are a number of new ETA selective blockers that
apparently do not have the same degree of hepatotoxic
effects as bosentan, their clinical usefulness is still unproven
because they have not yet been tested in large clinical trials
in patients with CHF. Well-designed, prospective, placebo-
controlled, randomized clinical trials using ET blockers
should be conducted. It is known that, despite the well-
proven benefits of therapy with ACE inhibitors, a signifi-
cant proportion of patients with CHF continue to be
symptomatic and remain at risk of death. A number of
recent studies have also shown that ET-1 levels are in-
creased in patients with CHF and predict adverse clinical
outcome and risk of death (15–17). Therefore, it would
seem reasonable to systematically examine the added
benefit of therapy with ET blockers on top of treatment
with ACE inhibitors and beta-blockers. This is especially
important in light of the findings from recent studies
showing significant reductions in levels of ET-1 after
treatment with beta-blocker therapy and treatment with
the ACE inhibitor fosinopril (21,22). Future studies
should also attempt to answer the critical question
regarding the role of ET-1 as a marker or mediator in
CHF. It is conceivable that ET-1 levels are more of a
marker of the severity of CHF because, as shown in the
studies with the ACE inhibitor fosinopril and beta-
adrenergic blocking agent, improvement in CHF status
itself is associated with reductions in ET-1 levels (21–22).
Clearly, more work is needed in this area before indepen-
dent role of ET-1 and the therapeutic rationale for its
blockade in CHF can be firmly established.
ENDOTHELINS IN SYSTEMIC HYPERTENSION
Because ET-1 is currently the most potent vasoconstrictor
known and because ET-1 also exerts profound renal effects,
it is not surprising that it has been incriminated in the
pathogenesis of systemic hypertension (1–6). There is,
however, a great deal of controversy regarding its role in
hypertension (6–8). It is known that chronic infusion of
ET-1 is associated with sustained increases in blood pres-
sure and that there is increased sensitivity to endothelin in
experimental models of hypertension (6,7). The role of
ET-1 in hypertension has been documented in patients with
hemangioendotheliomas and the cyclosporine-induced hy-
pertension by showing that removal of the tumor and
therapy with ET antagonist, respectively, restore blood
pressure to normal levels (7). However, despite these inter-
esting observations, the role of ETs in most of the popula-
tion with systemic hypertension remains questionable (6–
8). An interesting study by Mangieri et al. published earlier
in the Journal of the American College of Cardiology (9)
provided some new findings in this area. In this study,
Mangieri et al. evaluated the response of plasma ET-1
during handgrip exercise in normotensive young male off-
spring of hypertensive parents (9). Their results demon-
strated that, compared with offspring of normotensive
parents, there was significantly greater rise in ET-1 levels
during handgrip exercise in young offspring of hypertensive
patients (9). These findings suggest that high levels of ET-1
in these individuals might be an independent marker of risk
for developing hypertension later in life. It is conceivable
that the offspring of hypertensive parents already have
evidence of endothelial dysfunction, which precedes devel-
opment of hypertension and a high level of ET-1 produced
during handgrip exercise or mental stress is actually a
marker of endothelial dysfunction. The role of ET-1 in the
pathophysiology of hypertension, however, will remain un-
clear until future studies can determine whether ET-1 is a
marker, mediator, or both, in patients with hypertension.
ENDOTHELINS AND ATHEROSCLEROSIS
There is a growing body of evidence that suggests that ET
plays a significant role in the process of atherosclerosis at the
cellular level (10). The data available from both human and
experimental models of atherosclerosis have shown that the
production as well as the activity of ET are enhanced by
established risk factors such as hypercholesterolemia, hyperin-
sulinemia, hypertension and smoking (10). Oxidized LDL and
insulin are both strong stimuli for ET production and secre-
tion. This is not surprising, given the fact that all of these risk
factors cause endothelial dysfunction, and that endothelium is
the major source of ET production. It is known that, in
addition to its profound vasoconstrictive action on systemic
and coronary arteries, ET also has significant chemotactic and
mitogenic effects stimulating hypertrophy and hyperplasia of
vascular smooth muscle cells (10). In addition, ET can pro-
mote microvascular platelet thrombi by potentiating platelet
aggregation. Because all of these processes are important in the
development of atherosclerosis, ET potentially plays an impor-
tant role in the process of atherosclerosis. However, many
other neurohormones have similar properties, raising the crit-
ical question about the independent role of ET in atheroscle-
rosis. This question can only be answered by specific studies
designed to examine the relative roles of important vasoactive
hormones in the same experiment.
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ENDOTHELIN IN ACUTE ISCHEMIC
SYNDROMES AND MYOCARDIAL INFARCTION
Many studies have demonstrated that ET levels are consis-
tently increased in patients with acute ischemic syndromes and
MI (11–14). Mechanistically, the increase in ET levels in acute
ischemic syndromes could be multifactorial and related to
endothelial injury due to plaque fissuring or rupture, ischemia,
vasospasm and reperfusion. It is also known that thrombin,
which plays a pivotal role in acute MI, is a potent stimulus for
ET release. High levels of ET can also potentiate the effects of
other vasoactive peptides on the vessel wall. After MI, ET-1
can play a role in the process of LV remodeling by potentiating
the effects of catecholamines and angiotensin II on myocardial
cell hypertrophy. The important question is whether ET is a
marker or mediator in acute ischemic syndromes, especially
because it is known that ET is also an acute phase reactant.
Whatever the precise role may be, the data from several recent
studies show that ET levels rise rapidly after MI in most
patients (12–14). The ET levels usually return to baseline
within 72 h in patients with uncomplicated MI; however, in
patients with cardiogenic stroke, CHF, and LV dysfunction
after MI, the levels stay elevated beyond the acute phase
(13,14). Follow-up studies in these patients have shown that
higher levels of ET predict adverse long-term prognosis and
poor survival (13,14). Preliminary data from a recent study
suggest that nonselective ET receptor antagonists can block
the trophic effects of ET and reduce collagen synthesis, which
in turn can modify the process of postinfarction remodeling
(24). On the basis of these data, it would seem reasonable to
investigate if ET receptor blocker therapy is of clinical benefit
in high-risk, post-MI patients. It would, however, be critical to
examine whether the treatment with ET receptor blockers
adds to the proven cardioprotective effects of beta-blockers and
ACE inhibitors after MI.
FUTURE IMPLICATIONS
The available evidence suggests that, in addition to its
powerful vasoconstrictive action, ET-1 has several other
properties that could play a significant role in the patho-
genesis of many cardiovascular disorders. However, because
of the significant interactions of ET-1 with other vasoactive
substances, its independent role needs to be further exam-
ined. Many clinical studies have demonstrated increased
production and increased sensitivity to ET-1 in patients
with systemic hypertension, acute ischemic syndromes, MI,
CHF and pulmonary hypertension. Despite the available
data from published clinical studies in patients with cardio-
vascular conditions, the precise role of ET-1 in the patho-
physiologic processes of these conditions has not been
established. The important question remains: Is ET-1 a
marker, a mediator, or both, in these disorders? Clearly, we
need to obtain some clear answers to this fundamental
question before getting too enthusiastic and consumed with
the clinical usefulness of ET receptor blockers in cardiovas-
cular disorders.
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